0001628280-20-013399.txt : 20200909 0001628280-20-013399.hdr.sgml : 20200909 20200909163719 ACCESSION NUMBER: 0001628280-20-013399 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200909 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200909 DATE AS OF CHANGE: 20200909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKWELL MEDICAL, INC. CENTRAL INDEX KEY: 0001041024 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383317208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23661 FILM NUMBER: 201166886 BUSINESS ADDRESS: STREET 1: 411 HACKENSACK AVE., SUITE 501 CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 2489609009 MAIL ADDRESS: STREET 1: 411 HACKENSACK AVE., SUITE 501 CITY: HACKENSACK STATE: NJ ZIP: 07601 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20120530 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL, INC. DATE OF NAME CHANGE: 20120525 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 19970722 8-K 1 rmti-20200909.htm 8-K rmti-20200909
0001041024FALSE00010410242020-08-072020-08-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  September 9, 2020
 
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
 
Delaware000-2366138-3317208
(State or other jurisdiction
of incorporation)		(Commission File Number)(IRS Employer
Identification No.)
 
411 Hackensack Avenue, Suite 501, Hackensack, New Jersey 07601
(Address of principal executive offices, including zip code)
 
(248) 960-9009
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class Trading Symbol Name of Each exchange on which registered
Common Stock, par value $0.0001 RMTI Nasdaq Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐


 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 




Item 8.01        Other Events.

        On September 9, 2020, Rockwell Medical, Inc. (the “Company”) issued a press release announcing that the Company has entered into an exclusive license agreement with Jeil Pharmaceutical Co., Ltd. for the rights to commercialize Triferic (ferric pyrophosphate citrate) in South Korea. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01        Financial Statements and Exhibits.

(d) Exhibits        The following exhibit is being furnished herewith:

EXHIBIT INDEX
 
Exhibit No. Description
   
99.1 
104Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 ROCKWELL MEDICAL, INC.
   
Date: September 9, 2020By: /s/ Russell Ellison
  Russell Ellison
  Chief Executive Officer


 EX-99.1 2 ex-rmtix20200907xjeilp.htm EX-99.1 Document
reexhibit991image11.gif   
Exhibit 99.1

Rockwell Medical Enters into Exclusive License Agreement with Jeil Pharmaceutical Co., Ltd., for the Rights to Commercialize Triferic® in South Korea

-Sizable and growing market opportunity with over 78,000 patients receiving hemodialysis annually-

WIXOM, Mich., September 09, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has entered into an exclusive license agreement with Jeil Pharmaceutical Co., Ltd. (“Jeil”), for the rights to commercialize Triferic (ferric pyrophosphate citrate) in South Korea.

Under the terms of the license agreement, Jeil will be the exclusive development and commercialization partner for Triferic in South Korea and Rockwell Medical will supply the product to Jeil. In consideration for the license, Rockwell Medical will receive an upfront fee, and will be eligible for milestone payments and royalties on net sales.

Jeil has developed and supplied pharmaceutical products and contributed to the growth and development of the pharmaceutical industry in Korea since its founding in 1959. Jeil, listed on the Korea Composite Stock Price (KOSPI) index since 1988, has approximately 1,000 employees and more than $576 million is sales for the year ended 2019. Jeil will leverage its strong development and commercialization capabilities and local market expertise to promote Triferic to nephrologists in South Korea. A Joint Alliance Committee, comprised of members from Rockwell Medical and Jeil, will guide the development and execution for Triferic in South Korea. Jeil will be responsible for all regulatory and commercialization activities. Product sales are anticipated to begin in early 2022, subject to regulatory approval.

“We are pleased to announce the license agreement with Jeil and the establishment of a relationship between our two companies,” said Russell Ellison, M.D., President and Chief Executive Officer of Rockwell Medical. “With its substantial development and commercialization capabilities and local market expertise, Jeil is well positioned to ensure that hemodialysis patients have access to our innovative therapeutic across South Korea. Today’s news marks another meaningful advancement for Triferic, as we expand our global footprint and drive the long-term value of Triferic.”

“We welcome this opportunity to collaborate with Rockwell Medical to provide Triferic to patients on hemodialysis in South Korea,” said Suk-Je Sung, President and Chief Execute Officer of Jeil. “There remains a significant unmet need for innovative medicine to address iron deficiency in these patients, with more than 78,000 patients receiving hemodialysis every year and we expect the number of CKD dialysis patients to continue to increase and double by 2030.”

Torreya Partners acted as a financial advisor to Rockwell Medical for this transaction.

About Rockwell Medical

Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company’s initial focus is the treatment of anemia in end-stage kidney disease (ESKD). Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and

reexhibit991image11.gif   
Triferic AVNU, are the only FDA-approved therapeutics indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

About Triferic Dialysate and Triferic AVNU

Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management - with the potential to become the future standard of care.

Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to the bone marrow and maintain hemoglobin without increasing iron stores (ferritin). Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body) upon entry into the blood which is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no reports of anaphylaxis in over 1,000,000 patient administrations, addressing a significant medical need in overcoming Functional Iron Deficiency (FID) in ESKD patients.

Important Safety Information

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving Triferic in two randomized clinical trials.

Iron status should be determined on pre-dialysis blood samples. Post dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

The most common adverse reactions (≥3% and at least 1% greater than placebo) in controlled clinical studies include: procedural hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain in extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%), asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, the receipt of an upfront fee and milestone payments and royalties by Rockwell Medical, the timing of product sales in South Korea, the receipt of regulatory approvals in South Korea and the potential market opportunity for Triferic in South Korea. Words such as, “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “can,” “would,” “develop,” “plan,” “potential,” “predict,” “forecast,” “project,”

reexhibit991image11.gif   
“intend” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical’s SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to: the impact of the COVID-19 pandemic (including, applicable federal, state or local orders) on business and operating results; receipt of regulatory approval for Triferic in South Korea; our ability to achieve milestones and receive royalty payments; anticipated market opportunity in South Korea; and those risks more fully discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the period ended June 30, 2020 and of our Annual Report on Form 10-K for the year ended December 31, 2019, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

Triferic® is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office. All other product names, logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

CONTACTS
Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com

 EX-101.SCH 3 rmti-20200909.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 rmti-20200909_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 rmti-20200909_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 rmti-20200909_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 rmti-20200909_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 reexhibit991image11.gif begin 644 reexhibit991image11.gif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end XML 9 rmti-20200909_htm.xml IDEA: XBRL DOCUMENT 0001041024 2020-08-07 2020-08-07 0001041024 false 8-K 2020-09-09 ROCKWELL MEDICAL, INC. DE 000-23661 38-3317208 411 Hackensack Avenue, Suite 501 Hackensack NJ 07601 248 960-9009 false false false false Common Stock, par value $0.0001 RMTI NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Aug. 07, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 09, 2020
Entity Registrant Name ROCKWELL MEDICAL, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 000-23661
Entity Tax Identification Number 38-3317208
Entity Address, Address Line One 411 Hackensack Avenue, Suite 501
Entity Address, City or Town Hackensack
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07601
City Area Code 248
Local Phone Number 960-9009
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol RMTI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001041024
Amendment Flag false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://rockwellmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports rmti-20200909.htm ex-rmtix20200907xjeilp.htm rmti-20200909.xsd rmti-20200909_cal.xml rmti-20200909_def.xml rmti-20200909_lab.xml rmti-20200909_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rmti-20200909.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "rmti-20200909_cal.xml" ] }, "definitionLink": { "local": [ "rmti-20200909_def.xml" ] }, "inline": { "local": [ "rmti-20200909.htm" ] }, "labelLink": { "local": [ "rmti-20200909_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rmti-20200909_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rmti-20200909.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rmti", "nsuri": "http://rockwellmed.com/20200909", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200909.htm", "contextRef": "i52fe3229cf484fb9bfb0794bc54328fb_D20200807-20200807", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://rockwellmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "rmti-20200909.htm", "contextRef": "i52fe3229cf484fb9bfb0794bc54328fb_D20200807-20200807", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001628280-20-013399-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-20-013399-xbrl.zip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end